Investing in Kymera Therapeutics entails typical clinical-stage biotechnology risks, including potential clinical trial setbacks, regulatory delays or rejections by health authorities, high ongoing research expenditures, and the constant need for future capital-raising rounds prior to achieving commercial product sales. Additionally, biotechnology equities face intense scientific competition and market volatility. Investors must be prepared for sharp share price fluctuations driven by trial data readouts and broader shifts in life science sector sentiment.